IDEAS home Printed from https://ideas.repec.org/a/aza/jdpp00/y2024v6i4p332-343.html
   My bibliography  Save this article

Synthetic data and European General Data Protection Regulation: Ethics, quality and legality of data sharing

Author

Listed:
  • Dwivedi, Shalini

    (VP, Head of Medical Writing and Clinical Trial Transparency, Krystelis, India)

Abstract

Synthetic data is increasingly being used across the financial services, clinical research, manufacturing and transport industries. In clinical research, use cases for synthetic data include secondary analysis to identify novel treatment pathways, to develop healthcare policies, to evaluate research methods and, importantly, to evaluate research hypotheses without exposing real patients to potentially harmful experimental treatments. Methods for creating synthetic data in a manner that can reconcile the privacy of clinical trial participants while preserving the utility of data for analysis are rapidly evolving. However, challenges remain that include obtaining appropriate consent for the use of real patient data in the creation of synthetic datasets, eliminating bias in synthetic data and ensuring that data privacy concerns can be addressed.

Suggested Citation

  • Dwivedi, Shalini, 2024. "Synthetic data and European General Data Protection Regulation: Ethics, quality and legality of data sharing," Journal of Data Protection & Privacy, Henry Stewart Publications, vol. 6(4), pages 332-343, June.
  • Handle: RePEc:aza:jdpp00:y:2024:v:6:i:4:p:332-343
    as

    Download full text from publisher

    File URL: https://hstalks.com/article/8647/download/
    Download Restriction: Requires a paid subscription for full access.

    File URL: https://hstalks.com/article/8647/
    Download Restriction: Requires a paid subscription for full access.
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Keywords

    synthetic data; GDPR; anonymisation; personal data; data sharing; clinical trial transparency; data privacy; data protection; data transfer; reidentification risk;
    All these keywords.

    JEL classification:

    • K2 - Law and Economics - - Regulation and Business Law

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:aza:jdpp00:y:2024:v:6:i:4:p:332-343. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Henry Stewart Talks (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.